Stuttgart
20.10.26 | 21:32
6,600 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,550 | 6,650 | 21:54 | |
| 6,550 | 6,650 | 21:54 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | Full Transcript: Exagen Q2 2026 Earnings Call | 2 | Benzinga.com | ||
| 11.08. | Exagen auf Wachstumskonferenz von Canaccord Genuity: Turnaround gewinnt an Fahrt | 5 | Investing.com Deutsch | ||
| 04.08. | Exagen targets $72M-$75M 2026 revenue outlook as profitability nears breakeven | 4 | Seeking Alpha | ||
| 04.08. | Exagen Q2 2026 slides: record revenue, stock surges 30% on results | 2 | Investing.com | ||
| 04.08. | Exagen Q2 2026 slides: record revenue, stock surges 36% | 2 | Investing.com | ||
| 04.08. | EXAGEN INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 04.08. | Exagen GAAP EPS of -$0.13 beats by $0.06, revenue of $19.94M beats by $2.07M | 2 | Seeking Alpha | ||
| 04.08. | Exagen Inc. Reports Second Quarter 2026 Financial Results | 616 | GlobeNewswire (Europe) | Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to... ► Artikel lesen | |
| EXAGEN Aktie jetzt für 0€ handeln | |||||
| 04.08. | EXAGEN INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 21.07. | Exagen Inc.: Exagen to Announce Second Quarter Financial Results on August 4, 2026 | 1 | GlobeNewswire (USA) | ||
| 09.06. | EXAGEN INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | Exagen Inc.: Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus | 1 | GlobeNewswire (USA) | ||
| 12.05. | BTIG senkt Kursziel für Exagen auf 8 US-Dollar, bestätigt aber 'Buy'-Rating | 6 | Investing.com Deutsch | ||
| 12.05. | Exagen stock price target lowered to $8 by BTIG on valuation | 1 | Investing.com | ||
| 12.05. | Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time | 1 | Seeking Alpha | ||
| 11.05. | Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates | 1 | Zacks | ||
| 11.05. | Exagen: EPS übertrifft Schätzungen um 0,05 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 11.05. | EXAGEN INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Exagen beats top-line and bottom-line estimates; reaffirms FY26 outlook | 1 | Seeking Alpha | ||
| 11.05. | Exagen Inc. Reports First Quarter 2026 Results | 307 | GlobeNewswire (Europe) | CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,526 | +8,01 % | Teladoc Health, Inc.: Teladoc Health to Announce Third Quarter 2026 Financial Results | ||
| HIMS & HERS HEALTH | 26,240 | +4,46 % | Hims & Hers gains after German launch | ||
| SERNOVA BIOTHERAPEUTICS | 0,075 | +5,34 % | Sernova Biotherapeutics bekommt nur eine 4-: Warum unsere Experten so kritisch sind - Handeln Sie noch vor Börsenschluss! | ||
| CERENOME | 1,370 | -4,86 % | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,280 | -0,87 % | Atossa Therapeutics: Stammaktien handeln ab sofort gekoppelt mit Contingent Value Rights | ||
| HENRY SCHEIN | 75,50 | +0,67 % | Henry Schein Inc. Profit Advances In Q2 | MELVILLE (dpa-AFX) - Henry Schein Inc. (HSIC) announced earnings for its second quarter that Increases, from last yearThe company's bottom line totaled $94 million, or $0.82 per share. This... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| TANDEM DIABETES | 15,100 | +3,42 % | Tandem Diabetes Care, Inc.: Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets | Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,650 | -2,46 % | Joint Venture von Co-Diagnostics zu saudi-arabischem Fertigungsforum eingeladen | ||
| QUIDELORTHO | 11,195 | +0,09 % | QuidelOrtho Reports Q2 2026 Results: Full Earnings Call Transcript | ||
| AMBU | 10,230 | +2,10 % | Ambu A/S: Interim Report For Q3 | 25.8.2026 18:01:05 CEST | Ambu A/S |
Interim report (Q1 and Q3)
In Q3 2025/26, Ambu delivered organic revenue growth of 10.3%, driven by strong performance in Endoscopy Solutions growing 16.0% organically.... ► Artikel lesen | |
| VERU | 2,355 | +1,95 % | Oppenheimer reiterates Veru stock rating ahead of obesity trial data | ||
| LIFEWARD | 5,610 | -5,40 % | 6,4 Millionen US-Dollar pro Patient: Warum Medtronic, Lifeward und NurExone an drei Stufen der Rückenmarksversorgung ansetzen | ||
| CLOVER HEALTH INVESTMENTS | 3,890 | -2,02 % | Clover Health Investments, Corp.: Clover Health Earns Top Honors in U.S. News & World Report's 2027 Medicare Advantage Ratings Across Three States | ||
| SENSEONICS | 7,050 | -1,40 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen |
EXAGEN INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 6,600 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXAGEN INC finden Sie auf Wallstreet Online.